Anti-programmed-death-receptor-1 (PD-1) antibody (Pembrolizumab) induced pancreatitis diagnosed on 18F-FDG PET/CT.
J Pak Med Assoc
; 74(4): 825-826, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38751292
ABSTRACT
Immunotherapy related adverse events are commonly seen with immune check point inhibitors therapy. We report the case of a 40-year-old female diagnosed with stage IVB endometroid grade III endometrial cancer, on pembrolizumab immunotherapy, an anti-programmed-death-receptor-1 (PD-1) antibody. Patient was referred for 18F-FDG PET/CT for restaging. 18F-FDG PET/CT demonstrated diffuse increased FDG uptake throughout the body of the pancreas associated with fat stranding in the peripancreatic region, suggestive of pembrolizumab-induced pancreatitis. The diagnosis was confirmed by elevated amylase and lipase levels. immune-related adverse events (irAE) are frequently identified on 18F-FDG PET-CT, which may lead to early diagnosis, close clinical follow-up, and appropriate clinical management of immune-related adverse events.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatitis
/
Fluorodeoxyglucose F18
/
Antibodies, Monoclonal, Humanized
/
Positron Emission Tomography Computed Tomography
/
Antineoplastic Agents, Immunological
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
J Pak Med Assoc
Year:
2024
Document type:
Article
Affiliation country:
Omán
Country of publication:
Pakistán